ニュース

The deal helps solidify Anthropic’s commitment to the life sciences sector as it targets more enterprise clients.

Recent price target moves for Bristol-Myers Squibb, including adjustments to US$70, US$75 and US$60, sit against only a very small shift in one fair value estimate from US$63.04 to US$62.96. These changes reflect how differently analysts are weighing execution risk, late-stage pipeline potential and the impact of upcoming patent expiries when thinking about where the stock could trade next. As you read on, you will see how to make sense of this evolving narrative and what to watch as new data...

REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.

Bristol Myers Squibb (NYSE:BMY) is investing US$1b in a new manufacturing facility in Houston, aimed at expanding pharmaceutical production capacity and creating hundreds of local jobs. The company has also launched a collaboration with the Tigerlily Foundation focused on improving clinical trial access and health equity for underrepresented patient groups. Bristol Myers Squibb is a global biopharmaceutical company focused on developing and manufacturing treatments across oncology,...

Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.

Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

(Updates with Novo Nordisk's response in the fourth and fifth paragraphs.) The US Supreme Court o

Tempus AI Inc. announced a new collaboration initiative with Bristol Myers Squibb Co. aimed at improving clinical trial design and increasing the Probability of Technical & Regulatory Success across five initial development programs. The companies plan to use artificial intelligence,...

These stocks are facing adversity, but with high yields and cheap valuations, investors may be compelled to take a chance on them.

REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.

Tempus AI and Bristol Myers Squibb are expanding their collaboration to apply AI analytics and real world data to oncology and neuroscience drug development. The partnership focuses on using Tempus AI's multimodal patient data to inform clinical trial design, including programs in oncology and Alzheimer's disease. The agreement highlights growing pharmaceutical interest in AI driven tools that can address complex challenges in precision medicine research. Tempus AI, listed as NasdaqGS:TEM,...

The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning tradi

Shares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.

A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.

Shares tumbled after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Bristol-Myers Squibb (BMY) has just signed a collaboration and licensing agreement with Hengrui Pharma covering 13 early stage oncology, hematology and immunology programs, a large commitment that could reshape its future pipeline. See our latest analysis for Bristol-Myers Squibb. At a share price of $56.77, Bristol-Myers Squibb has a 1-year total shareholder return of 30.12%, while the year to date share price return of 6.19% and recent 90 day share price weakness suggest momentum has...

The long-time pharma exec is on a quest with a new book and bold message for biotech leaders and U.S. lawmakers.

Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, marking a 13.6% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

PFE targets high single-digit revenue CAGR from 2029 as new launches, acquisitions and pipeline growth may offset LOE headwinds.

RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.

Bristol-Myers will pay Hengrui up to $950 million by 2028 for 13 early-stage programs.

The two companies will trade the greater Chinese and US rights to certain programmes under their jurisdiction, while working in tandem to progress these assets.